DDIT3 and non-Hodgkin lymphoma: The recent Phase I clinical trial testing selinexor and R-CHOP in NHL involved patients receiving six 21-day cycles of R-CHOP and either 60 mg or 80 mg of weekly selinexor, followed by weekly selinexor maintenance for 1 year [43].